

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

**POLL RESULTS OF EXTRAORDINARY GENERAL MEETING
HELD ON 4 JANUARY 2023**

The Board is pleased to announce that the resolution proposed at the EGM held on 4 January 2023 was duly passed by the Shareholders by way of poll.

References are made to the notice of the extraordinary general meeting and circular (the “**Circular**”) of China Traditional Chinese Medicine Holdings Co. Limited dated 15 December 2022. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the EGM was held on 4 January 2023 and the resolution proposed at the EGM was duly passed by the Shareholders by way of poll.

As at the date of the EGM, there were a total of 5,035,801,852 Shares in issue, which was the total number of eligible Shares that entitled the Shareholders to attend and vote for or against the resolution at the EGM. CNPGC and its associates, who were interested in 1,634,705,642 Shares as at the date of the EGM (representing approximately 32.46% of the total issued Shares), have abstained from voting on the resolution relating to the New Master Supply Agreement at the EGM. Save for the above, no Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolution at the EGM. There were no Shares entitling the holders to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 13.40 of the Listing Rules.

The poll results in respect of the resolution were as follows:

Ordinary resolution	No. of votes cast and percentage of total no. of votes cast		Total no. of votes cast
	For	Against	
1. To approve the New Master Supply Agreement, the transactions contemplated thereunder and the annual caps for the sales for the three financial years ending 31 December 2023, 2024 and 2025.	1,366,493,119 (100%)	0 (0%)	1,366,493,119

As more than 50% of the votes were cast in favour of the above resolution, the resolution proposed at the EGM was duly passed as an ordinary resolution of the Company.

The executive Directors, Mr. CHEN Yinglong, Mr. CHENG Xueren and Mr. YANG Wenming; and the independent non-executive Directors, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong attended the EGM either in person or by electronic means.

Computershare Hong Kong Investor Services Limited, the share registrar of the Company, was appointed as the scrutineer for the purpose of counting the votes at the EGM.

By order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
CHEN Yinglong
Chairman

Hong Kong, 4 January 2023

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. CHEN Yinglong, Mr. CHENG Xueren and Mr. YANG Wenming are executive Directors; Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan, Mr. MENG Qingxin and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.